-Epilepsy is a debilitating condition affecting 1% of the population worldwide. Medications fail to control seizures in at least 30% of patients, and deep brain stimulation (DBS) is a promising alternative treatment. A modified clinical DBS hardware platform was recently described (PCϩS) allowing long-term recording of electrical brain activity such that effects of DBS on neural networks can be examined. This study reports the first use of this device to characterize idiopathic epilepsy and assess the effects of stimulation in a nonhuman primate (NHP). Clinical DBS electrodes were implanted in the hippocampus of an epileptic NHP bilaterally, and baseline local field potential (LFP) recordings were collected for seizure characterization with the PCϩS. Real-time automatic detection of ictal events was demonstrated and validated by concurrent visual observation of seizure behavior. Seizures consisted of large-amplitude 8-to 25-Hz oscillations originating from the right hemisphere and quickly generalizing, with an average occurrence of 0.71 Ϯ 0.15 seizures/day. Various stimulation parameters resulted in suppression of LFP activity or in seizure induction during stimulation under ketamine anesthesia. Chronic stimulation in the awake animal was studied to evaluate how seizure activity was affected by stimulation configurations that suppressed broadband LFPs in acute experiments. This is the first electrophysiological characterization of epilepsy using a next-generation clinical DBS system that offers the ability to record and analyze neural signals from a chronically implanted stimulating electrode. These results will direct further development of this technology and ultimately provide insight into therapeutic mechanisms of DBS for epilepsy. deep brain stimulation; hippocampus; temporal lobe epilepsy; local field potential EPILEPSY IS A COLLECTION of diverse disorders, varying in pathogenesis, site of seizure onset, and response to treatment. Temporal lobe epilepsy (TLE) is a common form of the disorder, characterized by seizures originating in the temporal lobe, most frequently in the hippocampus and amygdala. In cases where pharmacological therapy either fails to adequately control seizures or is not well tolerated, resective surgery is an effective treatment, suppressing disabling seizures in 50 -80% of patients undergoing mesial TLE (MTLE) resections (Engel et al. 2003). Seizure freedom occurs in fewer than 50% of patients undergoing extratemporal resections (de Tisi et al. 2011), however, and resective surgery is not an option for cases where the seizure focus is not well localized or when resection would cause unacceptable functional deficits. These problems, coupled with the nonreversible nature of resective surgery, underscore the need for new and more effective alternative treatments for medically refractory epilepsy. Deep brain stimulation (DBS) is a promising emerging therapy for focal epilepsy. Most efforts to date have focused on modulating nodes within the limbic circuit of Papez, a network often implica...